NVCR News and Press, NovoCure Limited From 04/25/24

2024-04-25 17:49:16 ET Summary The Annual Meeting of the American Society of Clinical Oncology is a major event for clinicians and researchers in the field of oncology. The plenary session will feature presentations on topics such as esophageal cancer, melanoma, and lung cancer. ...

Novocure (NASDAQ: NVCR) today announced the results of the METIS phase 3 clinical trial in brain metastases from non-small cell lung cancer (NSCLC) will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, to be held from May 31 to June 4. METIS was...

Novocure (NASDAQ: NVCR) today announced 20 presentations on Tumor Treating Fields (TTFields) therapy will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2024, to be held April 5 to 10 in San Diego. The presentations, describing preclinical investigations, i...

2024-04-01 17:08:57 ET Gainers: Zapata Computing  (ZPTA) +12% . Thoughtworks Holding ( TWKS ) +4% . Gain Therapeutics ( GANX ) +3% . Portillo's ( PTLO ) +3% . Vital Farms ( VITL ) +3% . Losers: Signature Bank ( OTC:SBN...

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2024 on Thursday, May 2, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three mo...

2024-03-30 06:34:10 ET Shares of Novocure (NASDAQ: NVCR) jumped 18.3% this week, according to data from S&P Global Market Intelligence , after the company announced encouraging results from a phase 3 study of its Tumor Treating Fields (TTFields) therapy for treating brain me...

2024-03-27 22:55:50 ET Summary NovoCure’s METIS trial met its primary endpoint but missed key secondary outcomes, casting doubt on TTFields' efficacy in NSCLC. Despite hitting the primary endpoint, TTFields’ role in NSCLC treatment is questionable without significant...

2024-03-27 08:25:49 ET DENVER, Colo., Mar 27, 2024 ( 247marketnews.com )- Novocure (NASDAQ: NVCR ) announced, this morning, that the phase 3 METIS clinical trial met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for a...

2024-03-27 07:50:51 ET More on NovoCure NovoCure Limited (NVCR) Q4 2023 Earnings Call Transcript NovoCure Limited 2023 Q4 - Results - Earnings Call Presentation NovoCure: Stay Cautious Amid Positive Signs NovoCure Q4 2023 Earnings Preview NovoCure Tum...

The METIS trial demonstrated 21.9 months median time to intracranial progression for patients treated with Tumor Treating Fields and supportive care compared to 11.3 months for patients treated with supportive care alone Novocure to host investor conference call at 8 a.m. EDT No...